A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in Treatment of Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Sintilimab (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Innovent Biologics
- 18 Oct 2018 According to an Innovent Biologics media release, the first patient has been dosed in the trial.
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 Planned number of patients changed from 22 to 74.